RESUMO
Because estrogens and the trigeminal system are inherently linked, prescribers who are treating a woman with a hormonally related mood disorder and migraine headaches should consider hormonal options to optimize the patient's treatment. This article discusses the interrelationships of estrogen, serotonin, and the trigeminal system as they relate to menstrual migraine occurrence and hormone-related mood symptoms. In addition, clinical examples are provided to facilitate the prescribers treating women during reproductive transitions in which declining estrogens are related to their suffering.
Assuntos
Estrogênios/uso terapêutico , Transtornos de Enxaqueca/tratamento farmacológico , Transtornos do Humor/tratamento farmacológico , Anticoncepcionais Orais Combinados , Contraindicações , Suplementos Nutricionais , Feminino , Humanos , Transtornos de Enxaqueca/etiologia , Transtornos de Enxaqueca/prevenção & controle , Gravidez , Complicações na Gravidez/tratamento farmacológico , Síndrome Pré-Menstrual/tratamento farmacológicoRESUMO
OBJECTIVE: To compare the effect of esterified estrogens and methyltestosterone versus esterified estrogens alone on diminished sexual interest in surgically menopausal women. DESIGN: This randomized, double-blind study compared the effect of combined esterified estrogens (1.25 mg) and methyltestosterone (2.5 mg) (EE/MT) versus esterified estrogens (1.25 mg) alone (EE) for 8 weeks. Several different sexual function questionnaires were used to measure response to therapy. Changes from baseline in sexual interest/function and hormone levels were evaluated after 4 and 8 weeks of treatment. RESULTS: A total of 102 women were randomized into the study; 52 (age range, 32-61 years) to EE/MT and 50 (age range, 33-62 years) to EE. After 8 weeks, significant differences between treatments were not seen in the Changes in Sexual Functioning Questionnaire (CSFQ-F-C) sexual desire/interest subscale score, the primary efficacy variable. In contrast statistically significant between-treatment differences were found for several secondary efficacy variables including Menopausal Sexual Interest Questionnaire (MSIQ) sexual interest/desire score, CSFQ-F-C arousal/erection subscale score and Women's Health Questionnaire sexual functioning subscale score. The mean serum concentration of bioavailable and free testosterone significantly increased, approximately doubling between baseline and the end of the study in patients receiving EE/MT, with a significant (P < 0.001) between-treatment difference. The mean serum concentration of sex hormone-binding globulin significantly decreased to less than one third of the pretreatment levels in patients receiving EE/MT (P < 0.001). Both treatments were well tolerated. CONCLUSIONS: The mixed results seen with the different sexual function questionnaires may be due to the CSFQ-F-C's lack of specificity for this population. Increased levels of bioavailable and free testosterone paralleled the improved MSIQ item scores. Both the EE and EE/MT treatments were well tolerated.
Assuntos
Anabolizantes/uso terapêutico , Estrogênios Esterificados (USP)/uso terapêutico , Estrogênios/uso terapêutico , Libido , Menopausa , Metiltestosterona/uso terapêutico , Adulto , Disponibilidade Biológica , Método Duplo-Cego , Terapia de Reposição de Estrogênios , Estrona/sangue , Feminino , Humanos , Pessoa de Meia-Idade , Globulina de Ligação a Hormônio Sexual/análise , Inquéritos e Questionários , Testosterona/sangue , Testosterona/farmacocinéticaRESUMO
OBJECTIVE: This study reports the results of a placebo-controlled, double-blind comparison of bupropion sustained release (SR) as an antidote for sexual dysfunction versus placebo in 42 patients with selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction. Exploratory analyses of the association of testosterone and sexual functioning in women in the study were also performed. METHOD: Patients with DSM-IV major depression who experienced a therapeutic response to any SSRI and were experiencing medication-induced global or phase-specific sexual dysfunction, as measured by the Changes in Sexual Functioning Questionnaire (CSFQ), were randomly assigned to receive either bupropion SR 150 mg b.i.d. or placebo for 4 weeks in addition to the SSRI. Total testosterone levels were assessed at baseline and week 4. RESULTS: The difference in global sexual functioning, based on the total CSFQ score, was not statistically significant between the 2 groups at week 4, nor were differences in orgasm, desire/ interest as measured by sexual thoughts, or self-reported arousal. There was a statistically significant difference between the 2 groups at week 4 in desire as measured by self-report feelings of desire and frequency of sexual activity. Desire/ frequency showed a significantly greater improvement among those patients receiving bupropion SR compared with placebo (Wilk's F = 5.47, df = 1, p =.024). Frequency was significantly correlated to total testosterone level at baseline (r = 0.36, p =.027) and at week 4 (r = 0.41, p =.025). CONCLUSIONS: Bupropion SR, as an effective antidote to SSRI-induced sexual dysfunction, produced an increase in desire to engage in sexual activity and frequency of engaging in sexual activity compared with placebo. A larger study is needed to further investigate this finding.
Assuntos
Antidepressivos de Segunda Geração/administração & dosagem , Antidepressivos de Segunda Geração/farmacologia , Bupropiona/administração & dosagem , Bupropiona/farmacologia , Transtorno Depressivo/tratamento farmacológico , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Disfunções Sexuais Fisiológicas/induzido quimicamente , Administração Oral , Adulto , Nível de Alerta , Preparações de Ação Retardada , Manual Diagnóstico e Estatístico de Transtornos Mentais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Placebos , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Testosterona/sangueRESUMO
Chronic episodic disorders, such as depressive disorders, IBS, migraine, and FMS, have important commonalities, including cormorbidities, an absence of classic anatomic pathology in the tissues, a lack of objective findings on physical examination, and a lack of abnormal findings by routine laboratory and radiologic tests. These CED are more prevalent in women (perhaps due to changes in estrogen levels), are generally worsened by stress (with resultant hyperactivity of the HPA axis), and often improve with aerobic exercise and common classes of medications affecting serotonin function, such as antidepressants. Thus, an increased understanding of the CED may result in improved treatment and functioning of many patients.
Assuntos
Transtorno Depressivo Maior/epidemiologia , Fibromialgia/epidemiologia , Síndrome do Intestino Irritável/epidemiologia , Transtornos de Enxaqueca/epidemiologia , Adulto , Doença Crônica , Comorbidade , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
Antidepressants are among the most widely prescribed medications in the United States. Adverse cutaneous drug reactions (ACDRs) associated with drugs are common, with possibly higher rates associated with psychotropic medications. While the vast majority of ACDRs are benign and easily treated, serious and life- threatening ACDRs, such as those associated with antidepressants, do rarely occur. ACDRs to antidepressants are diagnosed primarily on the basis of the patient's history. A clinician who is aware of these common and potentially serious adverse events will help avoid their continuation or recurrence. There are certain characteristics that place an individual at higher risk for an ACDR such as female gender, increasing age, African-American ethnicity, use of multiple medications and presence of a serious illness. If a cutaneous reaction occurs in an outpatient setting, it is advisable to discontinue the offending antidepressant and substitute it with one from another class. Treatment of the ACDR should be symptomatic if the patient shows no other significant signs of reaction. If other signs are present, however, a dermatology consultation should be obtained. Since the diagnosis of ACDRs is often tentative, and the exanthema is likely to be benign, the physician treating a patient with a mood or anxiety disorder must weigh the risk of developing these potential problems against the possibility of relapse of the psychiatric disorder should the medication be discontinued.
Assuntos
Antidepressivos Tricíclicos/efeitos adversos , Toxidermias/etiologia , Humanos , Dermatopatias/induzido quimicamenteRESUMO
Antipsychotic agents are known to cause adverse cutaneous reactions in approximately 5% of the individuals for whom they are prescribed. The majority of adverse cutaneous events are benign and easily treated, and do not place the patient at a serious health risk. However, these adverse events may impact on compliance so discussing strategies with the patient to avoid potential adverse cutaneous effects will improve compliance. The most frequently reported cutaneous adverse effects of antipsychotic medications include: exanthematous eruptions, skin pigmentation changes, photosensitivity, urticaria and pruritus. Only a small percentage of adverse cutaneous reactions are life threatening. The most important step in minimizing morbidity is prompt recognition of severe drug reactions with withdrawal of the causative medication. If a skin eruption occurs in an outpatient setting, it is generally advisable to discontinue the drug and to consider switching to another class of agent. If the reaction is mild, and the therapeutic benefits far exceed the risks of the symptomatic treatment, then the antipsychotic agent may be continued.
Assuntos
Antipsicóticos/efeitos adversos , Hipersensibilidade a Drogas/etiologia , Dermatopatias/induzido quimicamente , HumanosRESUMO
Of all the psychotropic medications currently available, the mood-stabilizing agents have the highest incidence of severe and life-threatening adverse cutaneous drug reactions (ACDRs). An exanthematous eruption in a patient treated with a mood-stabilizing agent should be viewed as possibly being the initial symptom of a severe and life-threatening ACDR, such as a hypersensitivity reaction, Stevens-Johnson syndrome, or toxic epidermal necrolysis. The combination of mood-stabilizing agents may increase the risk of such reactions. The mood-stabilizing agents addressed in this article are carbamazepine, lithium carbonate, valproic acid, topiramate, lamotrigine, gabapentin, and oxcarbazepine. Prior to the initiation of a mood stabilizer, the potential benefits, risks, and adverse effects should be communicated to the patient. If possible, slow dose escalation should be attempted by the physician. Patients should also be advised to seek medical attention if they suspect a drug-induced skin reaction. If the physician suspects a severe ACDR, the offending agent should be removed immediately.
Assuntos
Toxidermias/etiologia , Psicotrópicos/efeitos adversos , HumanosRESUMO
Are reproductive life events in women associated with an increased risk of sexual dysfunction? Female sexual dysfunction effects up to 40% of women in the United States between 18 and 59 years of age. Sexual dysfunction may be accompanied by fluctuations in gonadal hormone secretion, making women more vulnerable to sexual symptoms, especially during times of reproductive life events. Reproductive life events, such as the use of birth control pills, various phases of the menstrual cycles, postpartum and lactation states, and perimenopause, are highly correlated with changes in sex steroids. As an understanding of the role of sex steroids on sexual functioning is elucidated, clinicians will be able to offer more specific and effective treatment options for women during various phases of reproductive life. Several case studies are presented to illustrate the unique clinical considerations that a clinician must consider when treating the biologic component of female sexual dysfunction.
Assuntos
Acontecimentos que Mudam a Vida , Comportamento Sexual/psicologia , Adulto , Antidepressivos de Segunda Geração/uso terapêutico , Bupropiona/uso terapêutico , Feminino , Terapia de Reposição Hormonal , Humanos , Pessoa de Meia-Idade , Disfunções Sexuais Psicogênicas/tratamento farmacológico , Disfunções Sexuais Psicogênicas/psicologiaRESUMO
Psychiatric medications are among the most widely prescribed medications in the United States. Adverse cutaneous drug reactions are associated with psychiatric medications in approximately 2% to 5% of the individuals for whom they are prescribed. Although most adverse cutaneous drug reactions associated with psychotropic medications are benign and easily treated, some can be disfiguring or life-threatening, particularly those associated with the mood stabilizers. Adverse cutaneous drug reactions associated with antidepressants, antipsychotics, and mood stabilizers are reviewed, and important issues that are of concern for the dermatologist who must consider when and how to safely discontinue a psychotropic medication in their patients are presented.
Assuntos
Antipsicóticos/efeitos adversos , Toxidermias/etiologia , Hipersensibilidade a Drogas/etiologia , Psicotrópicos/efeitos adversos , Dermatopatias/induzido quimicamente , Humanos , Padrões de Prática Médica , Fatores de TempoRESUMO
This article reviews some common medical conditions and the interaction between those illnesses and depression in the geriatric population. The authors aim to help clarify the 2-way interaction between depression and these medical conditions, especially in older individuals, and impart some important diagnostic and treatment considerations to the practicing physician. The presence of multiple conditions further complicates treatment, as does associated medication use, substance abuse problems (often underappreciated in the elderly), age-related changes in sleep architecture, and an array of other psychosocial and environmental factors that can contribute to the development of depression.
Assuntos
Doenças Cardiovasculares/epidemiologia , Transtorno Depressivo/epidemiologia , Doenças do Sistema Endócrino/epidemiologia , Insuficiência Renal Crônica/epidemiologia , Idoso , Comorbidade , Transtorno Depressivo/tratamento farmacológico , Gastroenteropatias/epidemiologia , Avaliação Geriátrica , Humanos , Masculino , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/epidemiologiaRESUMO
This article reviews depressive symptoms in women as they relate to infertility and infertility treatments. Common causes of infertility in women are discussed and the literature on depressive symptoms before and during various infertility treatments is presented. Recommendations are made from a psychiatric perspective regarding how to manage depressive symptoms in women in the context of infertility.
Assuntos
Depressão/etiologia , Depressão/terapia , Infertilidade Feminina/psicologia , Infertilidade Feminina/terapia , Psicoterapia , Adulto , Clomifeno/uso terapêutico , Depressão/psicologia , Feminino , Fármacos para a Fertilidade Feminina/uso terapêutico , Humanos , Infertilidade Feminina/etiologia , Fatores de Tempo , Resultado do TratamentoRESUMO
This study evaluates websites relevant to female hypoactive sexual desire disorder (HSDD). Its primary aim is to evaluate the quality of Internet HSDD information. One hundred and one websites, identified through simple Google searches, were scored using a tool incorporating expert consensus-derived quality criteria for HSDD. The tool included structural criteria such as currency, authorship, and disclosure of competing interests. It also included performance criteria, evaluating accuracy, and comprehensiveness, and was adapted from a published website evaluation tool for diabetes. For each website, a quality index score with a potential range from 1 to 5 (1 = poor, 5 = excellent) was calculated, and the websites were rank ordered using this score. Quality index scores ranged from 1.68 to 4.64, with 75% of websites scoring at or below 3.27. Test-retest reliability was moderate (n = 24, r = 0.6601, P = .0004). Rank ordering of the websites by quality index allowed identification of the top five highest quality websites. The majority of HSDD websites' quality scores fell in the score range from 1 to 3, indicating room for improvement in the quality of websites that address HSDD. Website evaluation tools utilizing both structural and performance quality criteria may help clinicians to assist their patients in assessing the quality of Internet health information.
Assuntos
Educação em Saúde/normas , Disseminação de Informação/métodos , Internet/classificação , Internet/normas , Educação de Pacientes como Assunto/normas , Indicadores de Qualidade em Assistência à Saúde , Disfunções Sexuais Psicogênicas , Feminino , Educação em Saúde/estatística & dados numéricos , Humanos , Internet/estatística & dados numéricos , Educação de Pacientes como Assunto/estatística & dados numéricos , Reprodutibilidade dos Testes , Estados Unidos , Saúde da MulherRESUMO
INTRODUCTION: Approximately one out of four sexually active women in the United States uses some form of hormonal contraceptive method because they provide the most effective reversible method of birth control available. However, little attention has been paid to possible adverse effects of combined oral contraceptives (COCs) on sexual functioning. AIM: The aim of this study was to examine the potential effects of COCs on women with hypoactive sexual desire disorder (HSDD). It was hypothesized that female patients with generalized, acquired HSDD on COCs have lower androgen levels than those not on COCs. METHODS: The patients were healthy premenopausal women with HSDD, aged 22-50 years. Subjects had a history of adequate sexual desire, interest, and functioning. Participants were required to be in a stable, monogamous, heterosexual relationship and were screened for any medication or medical or psychiatric disorders that impact desire. The patients met operational criteria for global, acquired HSDD. The 106 patients were divided into two groups: those on COCs (N = 43) and those not on COCs (N = 63). A two-tailed t-test comparison was made between the two groups comparing free and total testosterone and sex hormone-binding globulin (SHBG). MAIN OUTCOME MEASURES: The main outcome measures are the differences between the two groups comparing free testosterone, total testosterone, and SHBG. RESULTS: These patients with HSDD on COCs had significantly lower free and total testosterone levels compared with those who were not on COCs. The SHBG was significantly higher in the group on COCs compared with those who were not on COCs. CONCLUSION: The result of this study suggests that COCs in premenopausal women with HSDD are associated with lower androgen levels than those not on COCs. Further research is required to determine if low androgen levels secondary to COCs impact female sexual desire.